Acceleron Pharma Inc(XLRN) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Current Price

$118.18

RSI

25.842

Beta:

0.40706

February 25, 2021
671M
17.1M
-39M

-81.351 %
110.297 %
99.931 %
38.087 %

$73,993,000
$73,993,000
$13,991,000
$13,481,000
$27,771,000
$18,097,000
0.000 %
428.861 %
3.783 %
-106.001 %
53.456 %

$-124,920,000
$-124,920,000
$-118,898,000
$-108,422,000
$-56,990,000
$-63,894,000
0.000 %
-4.821 %
-8.811 %
-47.437 %
12.114 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.